articleTop 1% cited
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Arthritis & Rheumatism · 2003 · Vol. 48(1) · pp. 35–45
Michael E. Weinblatt✉(Brigham and Women's Hospital)Edward Keystone(Mount Sinai Hospital)Daniel E. Furst(University of California, Los Angeles)Larry W. Moreland(University of Alabama at Birmingham)Michael H. Weisman(Cedars-Sinai Medical Center)C. Birbara(University of Massachusetts Amherst)Leah A. Teoh(Abbott (United States))Steven Fischkoff(Reckitt Benckiser (United States))Elliot Chartash(Reckitt Benckiser (United States))
Abstract
The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.
Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders ResearchChronic Lymphocytic Leukemia ResearchAdalimumabMedicineRheumatoid arthritisPlaceboMethotrexateConcomitantInternal medicineRheumatologyGastroenterologyTumor necrosis factor alpha
MeSH terms
AdalimumabAdultAgedAntibodies, MonoclonalArthritis, RheumatoidCombined Modality TherapyEnzyme PrecursorsFatigueFemaleHumansMaleMetalloendopeptidasesMethotrexateMiddle AgedSeverity of Illness Index
Citations
1,756
FWCI
82.70
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Cells · 2020 · 887 citations
Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development
Cells · 2018 · 471 citations
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Gastroenterology · 2006 · 1,710 citations
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Gut · 2007 · 1,030 citations
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
British Journal of Dermatology · 2007 · 720 citations
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
Arthritis & Rheumatism · 2004 · 1,165 citations
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Arthritis & Rheumatism · 2004 · 1,168 citations
Protein therapeutics: a summary and pharmacological classification
Nature Reviews Drug Discovery · 2007 · 2,066 citations
References
The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
Arthritis & Rheumatism · 1993 · 1,640 citations
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
Arthritis & Rheumatism · 1988 · 19,868 citations
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Arthritis & Rheumatism · 1995 · 2,833 citations
Guidelines for the management of rheumatoid arthritis: 2002 Update
Arthritis & Rheumatism · 2002 · 1,211 citations
The MOS 36-ltem Short-Form Health Survey (SF-36)
Medical Care · 1992 · 29,431 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.